Victoza (liraglutide) is a prescription drug used to help manage type 2 diabetes and reduce the risk of certain diabetes-related heart problems. Victoza is given as a daily injection under the ...

Novo Nordisk's Victoza (liraglutide) has become the only approved diabetes drug in the GLP-1 agonist class shown to demonstrate a cardiac safety benefit, although it faces competition from a ...

Victoza (liraglutide) and Ozempic (semaglutide) are two injectable drugs known as GLP-1 agonists used to treat people with type 2 diabetes. While some GLP-1 agonists are used for weight loss in ...

Novo Nordisk has settled a US patent case with Teva, which prevents the Israel-based generics firm marketing a cheaper version of its key type 2 diabetes drug Victoza until 2023.